OST-122 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	2

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04353791 (ClinicalTrials.gov)	September 16, 2020	24/3/2020	Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis	A Phase Ib/IIa, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral Treatment With OST-122 in Patients With Moderate to Severe Ulcerative Colitis	Ulcerative Colitis Chronic Moderate;Ulcerative Colitis Chronic Severe	Drug: OST-122;Drug: Placebo	Oncostellae S.L	NULL	Completed	18 Years	75 Years	All	32	Phase 1/Phase 2	Spain;Ukraine
2	EUCTR2019-004090-50-ES (EUCTR)	07/02/2020	11/11/2019	Clinical Trial to evaluate the safety and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis	A Phase Ib/IIa, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis	Moderate to severe ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: OST-122 INN or Proposed INN: Not available yet Other descriptive name: OST-122 Product Name: OST-122 INN or Proposed INN: Not available yet Other descriptive name: OST-122	ONCOSTELLAE S.L.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	32	Phase 1;Phase 2	Spain